Bortezomib,a proteasome inhibitor, is licensed as monotherapy, or in combination with pegylated liposomal doxorubicin or dexamethasone, for the treatment of multiple myeloma that has progressed despite the use of at least one therapy
Cancer Research and Antivirals
Send us your enquiry for Bortezomib. We offer custom pack sizes at special prices. We aim to respond to your enquiry within 24 hours.
We value your input so if you have suggestions regarding new applications for Bortezomib email us and we will include your contribution on the website.